The Best of EAU15: Urothelial Cancers
The Best of EAU15 continues to bring you highlights from our Annual Congress. This week, we present the best that EAU15 has to offer on urothelial cancers, as selected by experts in the field. Please enjoy this selection of free previews from the EAU15 Resource Centre!
Point-counterpoint: BCG alone - still the gold standard?
Yes: Amongst other points, Prof. Maximilian Burger points out that in non-muscle invasive high-risk bladder cancer BCG remains the sole form of treatment other than early cystectomy with solid evidence.
View webcast >
No: Dr. Kay Thomas contends that, while BCG is a great success story for urology, BCG alone is inadequate.
View webcast >
Molecular profiling in bladder cancer - The Cancer Genome Atlas (TCGA) project
Dr. Seth Lerner shares the latest data from the TCGA project, reviews key translatable findings and asks if urology is ready for personalized genomic therapy.
View webcast >
Extended lymph node dissection in bladder cancer – What is the evidence?
Prof. Jürgen Erich Gschwend presents the available information from published retrospective and prospective studies on extended versus limited lymph node dissection during radical cystectomy in bladder cancer.
View webcast >
Other presentations on urothelial cancer
Debate:
Is robotic cystectomy the future standard? - Yes
Prof. Peter Wiklund
View >
State-of-the-art lecture:
Immunotherapy - Bladder cancer
Dr. Thomas Powles
View >
State-of-the-art lecture:
When BCG fails
Prof. John Kelly
View >
More on Urothelial Cancer
If you attended EAU15, you can access all content when you log in with the barcode on your Congress Badge. For those who couldn't join us in Madrid, you can buy access to the EAU15 Resource Centre.
For €49 (EAU Members) or €89 (non-Members) you can review over 4,000 items of scientific content, ranging from webcasts, (e-)posters and abstracts to videos and presentations. Once you select an item, you will be prompted to log in and, if necessary, purchase access.
Copyright 2015 Uroweb, All rights reserved.
Why did I get this e-mail? | Unsubscribe from this list.
Engage with us and sign up for our newsletter.